

- Skin Contact:** Wash skin thoroughly with soap and water. If irritation develops, consult a physician
- Inhalation:** Not likely to occur under normal conditions of use.
- Ingestion:** Consult a physician or poison control center immediately.

SECTION 5: FIRE FIGHTING MEASURES

- Flash Point and Method:** N/A
- Flammable Limits** Not determined
- Autoignition Temperature:** No data for this product
- Fire-Extinguishing Materials:** Use extinguishing media suitable for materials supporting combustion such as water fog, CO₂, foam, or dry chemical.
- Fire Fighting Procedures:** Use self-contained breathing apparatus in enclosed or confined spaces or as otherwise needed.
- Unusual Fire and Explosion Hazards:** None known

SECTION 6: ACCIDENTAL RELEASE MEASURES

Sweep up or take up with absorbent material and wash with water. If large quantities are spilled, flush spill area with water.

SECTION 7: HANDLING AND STORAGE

- Handling:** Avoid unintentional contact with skin surfaces. Do not allow contact with eyes. Wash thoroughly after handling. Observe all labeling precautions and protective equipment recommendations.
- Storage:** Store in a cool, dry location out of direct sunlight. Keep container closed when not in use.

SECTION 8: EXPOSURE CONTROLS AND PERSONAL PROTECTION

- Engineering Controls:** None necessary for normal product handling.
- Respiratory Protection:** None necessary for normal product handling.
- Eye Protection:** None necessary for normal product handling. Avoid eye contact.
- Protective Clothing:** None necessary for normal product handling. Clinicians repeatedly applying the product to patients should wear latex gloves when handling **M.D. FORTE II® Glycolic Chemical Peel Gel**.
- Hygienic Work Practices:** Wash hands thoroughly after handling. No eating, drinking, or smoking in area.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

Vapor Density (Air = 1):	No data on this product
Boiling Point:	No data on this product
Solubility in water:	Dispersible
Specific Gravity:	1.24 - 1.28 @ 25°C
pH:	2.15 - 2.35 @ 25° C
Vapor Pressure (mm of Hg at 20° C):	No data on this product
Appearance and Odor:	Clear Gel

SECTION 10: STABILITY AND REACTIVITY

General: This product is stable and hazardous polymerization will not occur.

Incompatible Materials and Conditions to Avoid: Store away from oxidizers and heat. Store below 30° C.

Hazardous Decomposition: Carbon Dioxide and/or Carbon Monoxide.

SECTION 11: TOXICOLOGICAL INFORMATION

Oral:	Not Tested
Skin:	Method - Fifty subjects were enrolled in the study which entailed a total of 3 to 5 Glycolic Acid Peels during a 5 month period. The product was applied and left in place for 2 to 9 minutes depending on the patient's tolerance and reactivity. Results: No adverse reactions were noted (allergy, infection, scarring, or dyschromia) during the course of testing.
Ocular:	Product may produce moderate to severe irritation upon contact with eyes.
Sensitization:	Method - Fifty subjects were enrolled in the study which entailed a total of 3 to 5 Glycolic Acid Peels during a 5 month period. The product was applied and left in place for 2 to 9 minutes depending on the patient's tolerance and reactivity. Results: No adverse reactions were noted (allergy, infection, scarring, or dyschromia) during the course of testing.
Reproduction:	Not Tested
Mutagenicity:	Not Tested

SECTION 12: ECOLOGICAL INFORMATION

Persistence and Degradability: Readily and rapidly degradable

Aquatic Toxicity: No data available on this product

SECTION 13: DISPOSAL CONSIDERATIONS

For small amounts of **M.D. FORTE II® Glycolic Chemical Peel Gel**, discard as ordinary trash. For large quantities, contact Allergan for information on disposal options.

SECTION 14: TRANSPORT INFORMATION

Not a hazardous material for DOT, IATA, IMO, or TDG shipment.

SECTION 15: REGULATORY INFORMATION

TSCA (Toxic Substances Control Act):

Components of this product are listed on the TSCA Inventory.

CERCLA (Comprehensive Environmental Response, Compensation, and Liability Act):

This product contains no components subject to reporting or notification requirements.

SARA Title III (Superfund Amendments and Reauthorization Act):

311/312 Hazard Categories: Immediate Health

313 Reportable Ingredients: None

WHMIS (Workplace Hazardous Materials Information System - Canada):

Not regulated.

SECTION 16: OTHER INFORMATION

Revision Summary: MSDS Revised 6/20/01; Supersedes 9/25/96

The preceding information is based on available data and is believed to be correct. However, no warranty is expressed or to be implied regarding the accuracy of this information, the results to be obtained from the use thereof or the hazards connected with the use of the material. Since this information contained herein may be applied under conditions beyond our control and with which we may be unfamiliar, Allergan does not assume any responsibility for the results of its use. This information is furnished upon the conditions that the person receiving it shall make their own determinations of the effects, properties, and protections which pertain to their particular conditions.